论文部分内容阅读
对肾综合征出血热Ⅰ型灭活疫苗进行成本效益和效果分析，为肾综合征出血热免疫预防策略的制定提供依据。以建德市肾综合征出血热Ⅰ型灭活疫苗现场效果考核资料为基础，分５个不同年龄组队列，计算各组的效益费用比（ＢＣＲ）和费用效果比（ＣＥＲ）。各年龄组ＢＣＲ和ＣＥＲ均分别小于１和大于０。３０～３９岁年龄组ＣＥＲ值１１０８０８２元最小，接近于人均国民生产总值（１０８万元），其他各组ＣＥＲ均较大，灵敏度分析显示疫苗费、保护率和保护期对ＣＥＲ和ＢＣＲ影响大。高危人群２０～２９、３０～３９和４０～４９岁年龄组ＣＥＲ均小于人均国民生产总值。结论：预防接种肾综合征出血热灭活疫苗未获正效益；３０～３９岁年龄组，其次是４０～４９岁和２０～２９岁年龄组是首选接种人群；１５～５９岁高危人群均需接种疫苗，其中２０～４９岁是重点接种人群。
The cost-effectiveness and efficacy analysis of type I inactivated vaccine against hemorrhagic fever with renal syndrome provide the basis for the development of immune prevention strategies for hemorrhagic fever with renal syndrome. Based on the field effect assessment data of type I inactivated vaccine against renal syndrome of Renal syndrome in Jiande City, BCR and cost-effectiveness ratio (CER) were calculated in 5 cohorts of different age groups. In each age group, the CERs of both BCR and CER less than 1 and over 0.30 to 39 years old were the lowest, which was 1108082 yuan, close to the per capita gross national product (1 080000 yuan) Sensitivity analysis showed that vaccine costs, protection rates, and duration of protection had a major impact on CERs and BCRs. The CERs for high-risk groups aged 20-29, 30-39 and 40-49 are less than the GNP per capita. CONCLUSION: Vaccination with vaccination against hemorrhagic fever with renal syndrome has not been effective. In the age group of 30-39 years, followed by 40-49 years old and 20-29 years old group is the preferred vaccination population; Vaccination, of which 20 to 49 years of age are the key vaccination groups.